Oncologia

This state-of-the-art reference is your visual guide to the diagnosis of the full spectrum of breast lesions seen in core biopsy specimens, including difficult and borderline pathology. Case-based presentations correlating radiologic and pathologic findings, help pathologists, radiologists, and surgeons gain a better understanding of the entire pathology process, thus greatly improving diagnostic accuracy and subsequent therapy.

In 2007, between 40,000 and 50,000 people in the United States will be diagnosed with primary brain tumors, the majority of whom will be adults. Three times this number will develop metastatic brain tumors from cancer originating elsewhere in the body.This issue of "Neurologic Clinics" contains the following articles: Epidemiology of Brain Tumors (Wrensch, Claus); Molecular Pathogenesis of Brain Tumors and the Role of Stem Cells (Ligon, Kesari); Advances in Neuroimaging of Brain Tumors (Henson); Medical Management of Brain Tumor Patients (Schiff, Wen); Advances in Neurosurgery for Brain Tumors (Shaffrey); Advances in Radiation Therapy for Brain Tumors (Mehta); Novel Therapies for Brain Tumors (Wen, Schiff); Anaplastic Astrocytomas and Glioblastomas (Reardon); Anaplastic Oligodendrogliomas and Anaplastic Oligoastrocytomas (Van Den Bent); Low-Grade Gliomas (Lang, Gilbert); Brain Metastases (Deangelis); Benign Brain Tumors (Link); Primary CNS Lymphoma (Abrey); and Genetic Causes of Brain Tumors (Plotkin).

There can never be enough material in the public domain about cancers, and particularly breast cancer. This book adds much to the literature. It provides general information on breast cancer management and considers all new methods of diagnosis and therapy. It focuses on nuclear medicine modalities by comparing their results with other diagnostic and therapeutic approaches. The coverage provides readers with up-to-date knowledge on breast cancer as well as information on the advances in the field of diagnosis. It also details data on the development of some new modalities and provides a general overview of the available tools for breast cancer treatment.

With the recent discovery of JAK2 mutations in myeloproliferative disorders, medical science has taken a revolutionary stride forward toward understanding the pathogenesis of these diseases. This new advancement translates not only to a more rapid and reliable diagnosis, but also allows groundbreaking research into the development of new therapeutics. Written in an easy-to-follow text "Myeloproliferative Disorders" gives the practicing clinician a single source answer to classification, diagnosis, management, and recent advances in this disorder.

Multiple myeloma is the second most prevalent hematological malignancy, with over 55,000 new cases diagnosed each year. This exciting new text, edited by lauded authorities on the topic, stands as the only available reference to assemble, review, and synthesizes the latest studies on translational therapies and clearly explains the impact of molecular pathogenesis, biology, and prognostic factors on the diagnosis, prognosis, and individualization of treatment and the development of novel therapeutic options for patients with myeloma. Moving from the bench to the bedside to the forefront of therapeutic development, this source: helps clinicians and researchers effectively deploy therapeutic strategies into clinical practice reflects trends in the use of agents which target both the tumor cell and its bone marrow microenvironment to overcome resistance to conventional therapies considers the critical role of the bone marrow microenvironment in the regulation of growth, survival, and homing of multiple myeloma discusses novel therapies in phase I and phase II trials, focusing specifically on therapeutic options for patients with newly diagnosed or relapsed/refractory multiple myeloma addresses novel therapies for other plasma cell disorders, and provides the framework for the design of next generation agents and combination therapies covers the entire scope of translational work in multiple myeloma, from advances in molecular pathogenesis, to prognostic factors, immunotherapy, and new options for newly diagnosed and relapsed multiple myeloma patients

"Bone and Soft Tissue Pathology: A Volume in the Diagnostic Pathology Series", by Andrew L. Folpe, MD and Carrie Y. Inwards, MD, packs today's most essential bone and soft tissue pathology know-how into a compact, high-yield format! The book's pragmatic, well-organized approach - complemented by abundant full-color, high-quality illustrations and at-a-glance tables - makes it easy to access the information you need to quickly and accurately identify pathology specimens. Best of all, Expert Consult functionality provides online access to the full text of the book, downloadable illustrations for your personal use, and more. The result is a practical, affordable reference for study and review as well as for everyday clinical practice.

There has been major growth in understanding immune suppression mechanisms and its relationship to cancer progression and therapy. This book highlights emerging new principles of immune suppression that drive cancer and it offers radically new ideas about how therapy can be improved by attacking these principles. Following work that firmly establishes immune escape as an essential trait of cancer, recent studies have now defined specific mechanisms of tumoral immune suppression. It also demonstrates how attacking tumors with molecular targeted therapeutics or traditional chemotherapeutic drugs can produce potent anti-tumor effects in preclinical models. This book provides basic, translational, and clinical cancer researchers an indispensable overview of immune escape as a critical trait in cancer and how applying specific combinations of immunotherapy and chemotherapy to attack this trait may radically improve the treatment of advanced disease.It offers a synthesis of concepts that are useful to cancer immunologists and pharmacologists, who tend to work in disparate fields with little cross-communication. Drs. Prendergast and Jaffee are internationally recognized leaders in cancer biology and immunology who have created a unique synthesis of fundamental and applied concepts in this important new area of cancer research. It summarizes the latest insights into how immune escape defines an essential trait of cancer. It includes numerous illustrations including: how molecular-targeted therapeutic drugs or traditional chemotherapy can be combined with immunotherapy to improve anti-tumor efficacy; and how reversing immune suppression by the tumor can cause tumor regression.

Considerable progress is being made in the field of oncology, and the rapid expansion of available information can often make it difficult for the busy practitioner to know which decisions are most appropriate in a given circumstance. The success of the "Dana-Farber Cancer Institute Atlas of Diagnostic Oncology" has led to the development of a series of disease management handbooks designed to aid the clinician with his or her decision making in clinical practice. Written by highly eminent authors, each title is produced in full color and is richly illustrated throughout, providing a review of each cancer including its incidence, epidemiology, etiology and histopathology, together with the clinical features. Diagnostic studies and current clinical and pathological staging are also given. Detailed tables are provided with histopathological classification, diagnostic studies and, when important, prognostic factors. Current therapies are also discussed in detail, particularly in relation to metastatic disease.